BioAxone BioSciences Receives Notice of Allowance for Composition of Matter Patent Covering Novel ROCK2 Inhibitor

BioAxone BioSciences, Inc., a biotechnology company focused on
developing innovative drugs to treat neurotrauma and neurovascular
disorders today announced that the United States Patent and Trademark
Office (USPTO) has issued a Notice of Allowance for the U.S. patent
application (US 15/591,039). Upon issuance the patent will provide key
intellectual property protection for BA-2017, a novel ROCK2 inhibitor in
development to treat reperfusion injury in stroke. The claims cover the
core structure of a proprietary small molecule designed to reverse the
loss of endothelial barrier dysfunction that occurs in neurovascular
disorders of the central nervous system. Once issued, the patent will
expire in 2037, not including any patent term extensions. BioAxone is
currently conducting IND-enabling studies for development of an acute
care drug to repair the endothelial cell dysfunction that leads to risk
of edema and hemorrhagic transformation in stroke.

BA-2017 is part of the neurovascular-focused pipeline of Rho kinase 2
inhibitors in development by BioAxone. Rho kinase 2 (ROCK2) is a drug
target that plays a key role in propagating biological signals that
regulate brain endothelial cell barrier function. Inhibition of
overactivated ROCK2 restores endothelial cell barrier dysfunction in
animal models of stroke.

“A comprehensive patent portfolio is essential for potential partners to
commercially develop our drugs, and we have filed several patent
applications to cover promising compositions and therapies for our
catalogue of ROCK2 inhibitors,” said Lisa McKerracher, PhD, CEO,
BioAxone BioSciences. “This composition of matter patent is an important
addition to our IP portfolio as we work on therapies to restore cell
barrier function in various diseases. We look forward to continued
success with our programs to treat unmet needs.”

About BioAxone BioSciencesBioAxone BioSciences is a
clinical-stage biotechnology company based in Cambridge, MA, and is
developing innovative drugs to restore neurological function for
patients with spinal cord injuries and neurovascular disorders. The
company also has preclinical programs in restoring epithelial barriers
in gastrointestinal disease and in glaucoma. BioAxone is led by a team
of scientists renowned for their work on axon regeneration, diseases
involving Rho/ROCK signaling and cell barrier function. For more
information, visit http://www.bioaxonebio.com
and follow the company on Twitter at @BioAxone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005190/en/

Leave a Comment